Drug profile · INN
ivabradine hydrochloride
CORLANOR
ivabradine hydrochloride (CORLANOR) is a potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker. Route of administration: oral. Current US regulatory status: approved.
Drug details — ivabradine hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
ivabradine hydrochloride (CORLANOR) is a potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker
Primary target: Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is ivabradine hydrochloride?
ivabradine hydrochloride (CORLANOR) is a potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ivabradine hydrochloride?
CORLANOR is a marketed brand name for ivabradine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ivabradine hydrochloride?
ivabradine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.